|Articles|February 12, 2008
CEO of Genelabs Resigns
Author(s)BioPharm International Editors
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned.
Advertisement
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned. Until a successor is appointed, Irene A. Chow, executive chair of Genelabs’ board of directors, and Frederick W. Driscoll, CFO, will assume leadership responsibilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5